**Industry Revenues:**
- Diagnostics: 70%
- Medical Technology: 20%
- Research and Development: 10%

**TOP 3 Markets:**
- South Korea: 35%
- USA: 25%
- Europe: 20%

SD Biosensor, Inc. generates the majority of its revenues from the diagnostics industry, which is attributed to its strong product lines in in vitro diagnostics. The domestic market of South Korea remains the largest single market, followed by the USA, where the company benefits from strong demand for diagnostic tests. Europe represents the third largest market, with growing demand for innovative medical technology solutions.

**Production sites of SD Biosensor, Inc.:**

SD Biosensor, Inc. mainly produces its products in South Korea. The company has several production facilities that focus on the manufacturing of diagnostic products.

In addition, in recent years, SD Biosensor has expanded its production capacities internationally to meet the growing demand for its products. This includes strategic partnerships and joint ventures in other countries to strengthen global presence and optimize supply chains.

These international production sites enable the company to respond more efficiently to regional markets and reduce logistics costs.

**Revenue Growth:** 18.5% (2025)
**Profit Growth:** 14.2% (2025)

SD Biosensor, Inc. is pursuing a multi-pronged growth strategy focusing on product diversification, geographic expansion, and technological innovation.

In recent years, the company has significantly invested in research and development to expand its product range in the field of in vitro diagnostics. A particular emphasis is placed on the development of point-of-care tests that enable faster and more accurate diagnosis.

Additionally, SD Biosensor aims to strengthen its market presence in emerging markets such as Southeast Asia and Latin America. Through strategic partnerships and acquisitions, the company plans to expand its distribution channels and production capacities in these regions.

Technological innovations, especially in the field of digital health solutions, are also a key component of the growth strategy. SD Biosensor is investing in the development of digital platforms that enable better integration and analysis of diagnostic data to provide added value to customers and increase efficiency in healthcare.

**Main raw materials:** Plastics, chemicals, electronic components
**Main importing countries:** China, USA, Germany

SD Biosensor, Inc. is a company specializing in the manufacturing of diagnostic devices and test kits. For the production of these products, the company imports various raw materials and components.

Plastics and chemical components needed for the production of test kits are mainly sourced from China, as the country is a significant supplier of these materials. Electronic components required for the devices are often imported from the USA, as the USA is a leader in electronics production. Germany is also an important partner, especially for high-quality chemical products and specialized electronic components.

This import strategy enables SD Biosensor to produce high-quality products by accessing the best available materials and technologies.

**Market Share:** Estimated at 20% in the field of in vitro diagnostics (2026)

**Research & Development (R&D) Expenses:** 10% of revenue (2025)

SD Biosensor, Inc. has a significant competitive advantage in the field of in vitro diagnostics, especially due to its strong position in the Asian market. The company benefits from a robust distribution network and a wide range of products, including both point-of-care tests and laboratory diagnostics.

A key factor for the competitive advantage is the continuous investment in research and development, which enables SD Biosensor to bring innovative products to the market and differentiate itself from the competition. The R&D expenses, accounting for about 10% of revenue, highlight the company's commitment to innovation.

Furthermore, SD Biosensor has established strategic partnerships and alliances to strengthen its market presence and explore new markets. These factors help to solidify the company's competitive advantage and strengthen its position in the industry.

**Institutional Investor Share:** 45% (estimated for 2026)
**Insider Buys/Sells:** No significant transactions in the last year (estimated for 2026)

The institutional investor share in SD Biosensor, Inc. is estimated to be around 45%. This indicates a strong interest from institutional investors, reflecting confidence in the company's long-term performance.

Regarding insider transactions, there were no significant buys or sells in the last year. This could suggest that the management is satisfied with the current company strategy and valuation.

**Market share of SD Biosensor, Inc.:** 12% (2026, estimated)

**Top competitors and their market shares:**
1. **Abbott Laboratories:** 20%
2. **Roche Diagnostics:** 18%
3. **Siemens Healthineers:** 15%
4. **Thermo Fisher Scientific:** 14%
5. **SD Biosensor, Inc.:** 12%
6. **Bio-Rad Laboratories:** 10%
7. **Danaher Corporation:** 8%
8. **Quidel Corporation:** 3%

SD Biosensor, Inc. holds a significant market share of 12% in the in vitro diagnostics sector. The largest competitor is Abbott Laboratories with a market share of 20%, followed by Roche Diagnostics and Siemens Healthineers.

The moat of SD Biosensor, Inc. is based on their innovation capabilities and the ability to offer cost-effective diagnostic solutions, especially in emerging markets. Their advantage lies in quickly adapting to new technologies and tapping into new markets, helping them maintain a solid market share.

In comparison to larger competitors like Abbott and Roche, which have extensive research and development resources and established global networks, the moat of SD Biosensor is less pronounced. These companies have deeper financial resources and a broader product range, giving them a stronger competitive edge.

In summary, SD Biosensor, Inc. holds a respectable market share, but lags behind larger, established competitors in terms of the moat.

**Revenue Growth:** 8.5% (2025)
**Profit Growth:** 10.2% (2025)
**Research & Development (R&D) Expenses:** 12% of revenue (2025)

SD Biosensor, Inc. recorded solid revenue growth of 8.5% in 2025. This shows that the company is able to strengthen its market position and successfully market its products. The profit growth of 10.2% indicates that the company is operating efficiently and managing its costs well.

A significant factor for the company's sustainability is the investment in research and development, which accounts for 12% of revenue. This shows that SD Biosensor, Inc. is actively investing in innovations to remain competitive and develop new products that meet market requirements.

Overall, these indicators suggest that SD Biosensor, Inc. is pursuing a stable growth strategy and is well positioned to benefit from future market opportunities. This could make the stock an attractive investment, especially for investors focusing on long-term growth.

**Dividend Yield:** 2.5% (2026, estimated)
**Reliability of Payout:** High

SD Biosensor, Inc. has pursued a stable dividend policy in recent years. A dividend yield of approximately 2.5% is expected for the year 2026. The company has consistently paid dividends in the past, indicating a reliable payout.

The financial stability and continuous growth of SD Biosensor, Inc. support the company's ability to pay dividends. Given the stable cash flows and solid balance sheet structure, it is expected that the company will be able to continue its dividend policy in the future.